BA
ZYNE

Bristlecone Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Bristlecone Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-672
Closed -$6K – 268
2017
Q3 		$6K Buy
+672
New +$7.11K ﹤0.01% 270

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bristlecone Advisors's ZYNE Position: Q4 2017 in Review

Bristlecone Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2017, closing a stake of 672 shares — an estimated $6K sold.

Bristlecone Advisors first reported a position in ZYNE in Q3 2017 and held it in 1 quarter. The position peaked at $6K in Q3 2017. 64 funds tracked by Wall St. Rank hold ZYNE as of Q4 2017.

  • Bristlecone Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2017 after selling out during the quarter.
  • Bristlecone Advisors sold 672 Zynerba Pharmaceuticals, Inc shares in Q4 2017, an estimated $6K.
  • Bristlecone Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and held it in 1 quarter.
  • Bristlecone Advisors's Zynerba Pharmaceuticals, Inc position peaked at $6K in Q3 2017.
  • 64 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2017.

Based on Bristlecone Advisors's 13F filing for Q4 2017, filed 30 Jan 2018.